A detailed history of Slate Stone Wealth, LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Slate Stone Wealth, LLC holds 14,895 shares of CTKB stock, worth $97,562. This represents 0.01% of its overall portfolio holdings.

Number of Shares
14,895
Previous 12,500 19.16%
Holding current value
$97,562
Previous $70,000 18.57%
% of portfolio
0.01%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$4.73 - $6.73 $11,328 - $16,118
2,395 Added 19.16%
14,895 $83,000
Q2 2024

Jul 25, 2024

BUY
$5.3 - $6.91 $66,250 - $86,375
12,500 New
12,500 $70,000

Others Institutions Holding CTKB

About Cytek Biosciences, Inc.


  • Ticker CTKB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 134,627,008
  • Market Cap $882M
  • Description
  • Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...
More about CTKB
Track This Portfolio

Track Slate Stone Wealth, LLC Portfolio

Follow Slate Stone Wealth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Slate Stone Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Slate Stone Wealth, LLC with notifications on news.